skip to main content

Press Releases Archive

September 10, 2019

Prevail Therapeutics Provides Program Update on PR001 in Parkinson’s Disease with GBA1 Mutations and Neuronopathic Gaucher Disease

Download
August 14, 2019

Prevail Therapeutics Reports Second Quarter 2019 Financial Results and Recent Business Highlights

Download
July 8, 2019

Prevail Therapeutics Receives U.S. FDA Fast Track Designation for PR001 for the Treatment of Parkinson’s Disease Patients with a GBA1 Mutation

Download
June 4, 2019

Prevail Therapeutics Announces IND Active for Phase 1/2 Trial of its Gene Therapy PR001 to Treat Parkinson’s Disease Patients with GBA1 Mutations

Download
August 9, 2017

The Silverstein Foundation, REGENXBIO, and OrbiMed Launch Prevail Therapeutics

Download

You are now leaving prevailtherapeutics.com

You've clicked on a link for a third-party site, which Prevail Therapeutics does not control, influence, or endorse. Prevail is not responsible for any content on this third-party site, including the privacy policy. Click "Continue" to leave or "Go Back" to return to prevailtherapeutics.com

Continue
Top